Interferon‐α therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy
- 1 September 2000
- journal article
- clinical trial
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 7 (5), 382-386
- https://doi.org/10.1046/j.1365-2893.2000.00246.x
Abstract
Hepatitis B e antigen (HBeAg) was quantified before, during and after interferon-α administration in a trial of 162 chronic hepatitis B patients treated for 16 or 32 weeks. In 139 of these patients we examined the prognostic value of the pretreatment level of HBeAg and the reduction in HBeAg level at weeks 4 and 8 for response at week 16. Multivariate analysis showed that the HBeAg pretreatment level is a highly significant predictor of response (judged as HBeAg and hepatitis B virus [HBV] DNA negativity), followed by a decrease in HBeAg from the start of therapy to week 8. During the first 8 weeks of therapy, a decrease in HBeAg of less than 40%, as observed in 30% of the patients, consistently resulted in non-response. After 16 weeks of treatment, non-responding patients were randomly assigned to receive no further treatment (n=57) or prolonged treatment for another 16 weeks (n=61). In both groups, changes in the HBeAg level from the start of (the first) therapy to week 8, but not the pretreatment HBeAg level itself, were significantly related to the response at week 52 (the end of follow-up). Changes in the HBV DNA level had no additional predictive value for response at weeks 16 or 52. Therefore, instead of sequential HBV DNA assessment, we recommend monthly monitoring of HBeAg during IFN-α therapy.Keywords
This publication has 8 references indexed in Scilit:
- Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatmentHepatology, 1999
- Serum HBeAg quantitation during antiviral therapy for chronic hepatitis BJournal of Medical Virology, 1997
- Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV DNA in monitoring the response to treatment in patients with chronic hepatitis BJournal of Viral Hepatitis, 1997
- The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trialsJournal of Hepatology, 1994
- Monitoring of antiviral therapy with quantitative evaluation of hbeag: A comparison with HBV DNA testingHepatology, 1993
- Eurohep: A European Community sponsored concerted action on viral hepatitis: its rationale and executionJournal of Hepatology, 1992
- A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis BNew England Journal of Medicine, 1990
- Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictive factorsHepatology, 1989